# GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

> **NCT05913388** · PHASE2 · RECRUITING · sponsor: **Providence Health & Services** · enrollment: 92 (estimated)

## Conditions studied

- Metastatic Melanoma
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** GB1211
- **DRUG:** Pembrolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05913388
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-29
- **Primary completion:** 2028-02
- **Final completion:** 2030-02
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05913388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05913388, "GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05913388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*